"i didn't see a direct link between shRNA GT and the bluebird programme yet, but it's warm, very warm."
John Maranganore (CEO Alnylam) is on Bluebird's BOD. They would likely collaborate with Alnylam (as they have a cross-licence agreement with BLT) rather than BLT directly.
Of course, any drug Bluebird developed using ddRNAi would be subject to royalties to BLT.
- Forums
- ASX - By Stock
- BLT
- celgene bluebird gene therapy cancer collab
celgene bluebird gene therapy cancer collab, page-4
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries